Literature DB >> 34815956

Early surgery can improve the outcomes of patients with severe tricuspid regurgitation undergoing tricuspid replacement.

Kun Hua1, Rui Zhao2, Zhan Peng1, Yunxiao Yang1, Osmanaj Florian1, Bin Mao1, Xiubin Yang1,2.   

Abstract

BACKGROUND: Tricuspid regurgitation (TR) usually remains asymptomatic for a long time, such that it is most often diagnosed at an advanced stage of right heart failure. The purpose of this study was to identify clinical characteristics and overall outcomes in patients with severe TR who received tricuspid valve replacement (TVR) at different clinical stages.
METHODS: Between 1993 and 2018, 256 severe TR patients who received TVR alone or in combination with other procedures were assessed at Beijing Anzhen Hospital. Ninety-three patients underwent New York Heart Association (NYHA) class I/II operations (early surgery group), and the others underwent NYHA class III/IV operations. The primary outcome was in-hospital and long-term mortality. Clinical outcomes were evaluated by the Kaplan-Meier method and Cox regression models. Follow-up was conducted annually. Propensity score matching and overlap propensity score weighting were performed as sensitivity analyses.
RESULTS: Postoperative complications, including low cardiac output (11.8% vs. 26.4%, P<0.001), renal failure (2.2% vs. 16.6%, P<0.001), and bleeding (3.2% vs. 11.7%, P=0.037), were significantly lower in the NYHA class I/II group than in the NYHA III/IV group. Patients in the NYHA class III/IV group had a significantly higher incidence of in-hospital mortality (18.4% vs. 5.4%, P<0.001) and long-term mortality (33.7% vs. 11.8%, P=0.006) after follow-up (median follow-up duration =63 months). The results indicated a consistently higher occurrence rate in the propensity score-matched cohort and overlap propensity score weighted analysis.
CONCLUSIONS: Consistent with the recent clinical trend to provide earlier and more aggressive TR intervention, our results indicate that surgery for severe TR patients should be considered before advanced heart failure develops, when patients are asymptomatic or mildly symptomatic (NYHA class I/II). 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  New York Heart Association classification (NYHA classification); Tricuspid regurgitation; tricuspid surgery

Year:  2021        PMID: 34815956      PMCID: PMC8569269          DOI: 10.21037/cdt-21-311

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  22 in total

1.  Effect of mitral valve repair on exercise tolerance in asymptomatic patients with organic mitral regurgitation.

Authors:  Juraj Madaric; Patrick Watripont; Jozef Bartunek; Filip Casselman; Marc Vanderheyden; Frank Van Praet; William Wijns; Ann Feys; Hugo Vanermen; Bernard De Bruyne
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

2.  Asymptomatic degenerative mitral regurgitation repair: Validating guidelines for early intervention.

Authors:  Anand Desai; James D Thomas; Robert O Bonow; Jane Kruse; Adin-Cristian Andrei; James L Cox; Patrick M McCarthy
Journal:  J Thorac Cardiovasc Surg       Date:  2020-11-30       Impact factor: 5.209

3.  What Is the Best Option in Patients With Isolated Severe Tricuspid Regurgitation?

Authors:  Mizuki Miura; Maurizio Taramasso; Mara Gavazzoni; Michel Zuber; Francesco Maisano
Journal:  J Am Coll Cardiol       Date:  2019-12-03       Impact factor: 24.094

Review 4.  Transcatheter Tricuspid Valve Interventions: Landscape, Challenges, and Future Directions.

Authors:  Lluis Asmarats; Rishi Puri; Azeem Latib; José L Navia; Josep Rodés-Cabau
Journal:  J Am Coll Cardiol       Date:  2018-06-26       Impact factor: 24.094

5.  Tricuspid regurgitation: what is the real clinical impact and how often should it be treated?

Authors:  Azeem Latib; Francesco Grigioni; Rebecca T Hahn
Journal:  EuroIntervention       Date:  2018-08-31       Impact factor: 6.534

6.  Long-term outcomes of patients undergoing tricuspid valve surgery†.

Authors:  Nishant Saran; Joseph A Dearani; Sameh M Said; Kevin L Greason; Alberto Pochettino; John M Stulak; Simon Maltais; Sertac Cicek; Juan Crestanello; Richard C Daly; Katherine S King; Hartzell V Schaff
Journal:  Eur J Cardiothorac Surg       Date:  2019-11-01       Impact factor: 4.191

7.  Should patients with severe degenerative mitral regurgitation delay surgery until symptoms develop?

Authors:  A Marc Gillinov; Tomislav Mihaljevic; Eugene H Blackstone; Kristopher George; Lars G Svensson; Edward R Nowicki; Joseph F Sabik; Penny L Houghtaling; Brian Griffin
Journal:  Ann Thorac Surg       Date:  2010-08       Impact factor: 4.330

8.  Impact of tricuspid regurgitation on long-term survival.

Authors:  Jayant Nath; Elyse Foster; Paul A Heidenreich
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

9.  Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation.

Authors:  Andrea L Axtell; Vijeta Bhambhani; Philicia Moonsamy; Emma W Healy; Michael H Picard; Thoralf M Sundt; Jason H Wasfy
Journal:  J Am Coll Cardiol       Date:  2019-05-06       Impact factor: 24.094

10.  Late Outcomes of Valve Repair Versus Replacement in Isolated and Concomitant Tricuspid Valve Surgery: A Nationwide Cohort Study.

Authors:  Wang-Kin Wong; Shao-Wei Chen; An-Hsun Chou; Hsiu-An Lee; Yu-Ting Cheng; Feng-Chun Tsai; Kuang-Tso Lee; Victor Chien-Chia Wu; Chun-Li Wang; Shang-Hung Chang; Pao-Hsien Chu
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.